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1INTRODUCTION 
 Streptococcus pneumoniae, a leading cause of morbidity and mortality in the 
United States, is the most common cause of community-acquired pneumonia, bacterial 
meningitis, acute otitis media, and bacteremia.1 Pneumococcal infections are among the  
most common reasons for acute-care office visits and hospitalization, and cause an 
estimated 40,000 deaths annually in the United States.2,3 Although S. pneumoniae was 
once considered to be uniformly susceptible to penicillin, the prevalence of 
pneumococcal isolates resistant to penicillin and other antimicrobial agents has increased 
substantially in the United States since the early 1990s.1,4-8 
The emergence of drug-resistant S. pneumoniae complicates the treatment of 
pneumococcal infections, which are often treated empirically, without knowing whether 
the infecting strain is susceptible or resistant to the antibiotic selected. Because 
geographical variations in the prevalence drug-resistant S. pneumoniae have been 
demonstrated,4,6,9 information about its regional prevalence is essential for the selection 
of appropriate antimicrobial therapy. Inappropriate antimicrobial use, such as treating 
infections with overly broad-spectrum antibiotics, can contribute to the increase of drug-
resistant S. pneumoniae in a population.1 There is also the problem of treatment failures 
occurring when infections caused by resistant strains are treated with ineffective 
antibiotics.10 
Surveillance of emerging infections such as drug-resistant S. pneumoniae is an 
integral part of preventing and controlling the spread of disease. Prevalence data obtained 
2by surveillance programs can identify changing patterns of resistance and be used by 
public health officials to develop interventions for specific communities or regions.11 
These interventions include issuing guidelines for appropriate antimicrobial treatment, 
identifying populations at risk for transmission of drug-resistant S. pneumoniae, and 
making recommendations concerning pneumococcal vaccination.12-14 
Prior to 1993, little was known about the prevalence of drug-resistant S.
pneumoniae in Connecticut or in other parts of the United States. Working with the 
Connecticut Department of Public Health (CDPH), I conducted a survey of all hospitals 
with clinical microbiology laboratories in Connecticut to determine the prevalence of 
penicillin resistance among isolates of S. pneumoniae in 1992-1993.15 To determine 
whether the prevalence of resistant S. pneumoniae has increased since this first laboratory 
survey was conducted, active hospital laboratory-based surveillance for invasive S.
pneumoniae began in March 1995. This was done as part of an Emerging Infections 
Program (EIP), which is a collaboration between the CDPH and the Centers for Disease 
Control and Prevention (CDC). 
 The collection of antimicrobial resistance data by a hospital laboratory-based 
surveillance program depends on the ability of hospital laboratories to accurately detect 
resistant isolates. However, there have been few studies to assess if clinical laboratories 
follow recommended protocols, the specific methods laboratories use for susceptibility 
testing of pneumococcal isolates, and the accuracy of susceptibility test results. The 
laboratory survey conducted in 1993 revealed that not all hospital laboratories in 
3Connecticut were following recommended guidelines for penicillin susceptibility testing 
of S. pneumoniae. A similar survey of acute-care hospital laboratories in Connecticut was 
conducted in 1995 to determine what methods hospital laboratories were using then to 
test pneumococcal isolates for antimicrobial susceptibility and what changes had occurred 
in susceptibility testing practices since 1993. 
 In this paper I will present background information on the emergence of drug-
resistant S. pneumoniae and information regarding laboratory methods used to detect 
antimicrobial susceptibility. I will then present the results of surveillance for penicillin-
resistant S. pneumoniae in 1992-1993 and 1995-1996, changes in laboratory susceptibility 
testing practices that occurred between 1993 and 1995, and an assessment of the accuracy 
of susceptibility test results reported by hospital laboratories in 1995-1996. 
4BACKGROUND 
The History and Emergence of Drug-Resistant S. pneumoniae 
 When penicillin was first introduced in the 1940’s it was hailed as a “miracle 
drug” in the fight against deadly bacterial infections.16 It is estimated that the 
introduction of penicillin reduced the mortality due to pneumococcal infections by about 
50% for all ages.17 Alexander Fleming, the discoverer of penicillin, warned in 1945 that 
misuse of penicillin could lead to the selection and propagation of mutant forms of 
resistant bacteria.16 Fleming himself had been able to produce resistant strains of bacteria 
in his laboratory by growing susceptible strains in increasingly higher amounts of 
penicillin.16 
The first clinical isolates of S. pneumoniae resistant to penicillin were reported 
from Australia and New Guinea in the late 1960’s.18,19 In 1977, pneumococcal strains 
that were highly resistant to penicillin were reported from South Africa,20 and large 
increases in the prevalence of resistant S. pneumoniae occurred in Spain and Hungary in 
the 1980’s.21-24 Pneumococcal isolates resistant to penicillin and to other antimicrobial 
agents have now been detected throughout the world.25-31 
In the United States, the prevalence of S. pneumoniae nonsusceptible to penicillin 
was relatively low during the 1980’s and then increased dramatically during the early 
1990’s.31 The results of surveillance studies conducted in the United States that have 
determined the prevalence of penicillin resistance of S. pneumoniae are presented in 
Table 1. The CDC has conducted national hospital-based surveillance for drug-resistant 
5S. pneumoniae since 1979 using isolates submitted by hospital laboratories participating 
in the Pneumococcal Sentinel Surveillance System.1,4,9 Data from these studies show that 
the prevalence of isolates nonsusceptible to penicillin increased from 5.0% in 1979-1987, 
to 6.6% in 1991-1992, to 14.1% in 1993-1994; and the prevalence of isolates highly 
resistant to penicillin increased from 0.02% to 1.3% to 3.2% during the same time 
period.1,4,9 Other national surveys conducted in the United States have also shown a 
marked increase in the prevalence of penicillin-nonsusceptible S. pneumoniae,6-8,32,33 with 
figures as high as 27%8 (Table 1). 
 Variations in the prevalence of penicillin-nonsusceptible S. pneumoniae reported 
by different surveillance studies could be due to differences in the patient population 
sampled. Surveillance studies that examined isolates collected from different 
geographical locations demonstrated that the prevalence of penicillin resistance often 
varied from one region to another.4,6,9 Patient’s age has also been associated with 
variations in the prevalence of resistance, with penicillin-nonsusceptible isolates being 
more common in children than adults.1,4,6 Epidemiological studies that examined racial 
differences in prevalence found that whites were more likely to have isolates resistant to 
penicillin than blacks.1,35,37,39 
The proportion of isolates tested from different body sites can have an impact on 
the percentage of isolates identified as resistant. Many studies have shown that isolates 
obtained from normally sterile sites (i.e., blood and cerebrospinal fluid) have lower rates 
of resistance than isolates obtained from non-sterile body sites.8,9,33,37,38 Surveillance 
6studies that included a relatively large percentage of isolates from non-sterile body sites 
reported high rates of penicillin-nonsusceptible S. pneumoniae6,8,32 (Table 1). 
 Pneumococci frequently colonize the upper respiratory tract of many individuals, 
and drug-resistant strains can be easily transmitted to others. Young children are very 
susceptible to pneumococcal infection, especially in settings such as day care centers.40 
Another way to assess the prevalence of drug-resistant S. pneumoniae is to determine 
pneumococcal colonization rates in specific populations such as day care centers.11,41,42 
Studies conducted in the United States have reported colonization rates of penicillin-
nonsusceptible S. pneumoniae in day care centers to be between 21% and 61%.43-46 
Many surveys have also reported an increase in the prevalence of S. pneumoniae 
resistant to other antibiotics in addition to penicillin. The most recent CDC hospital 
surveillance study reported that 26% of the isolates tested were nonsusceptible to more 
than one antimicrobial agent.1 Strains that are resistant to penicillin are also often 
resistant to cefotaxime or ceftriaxone, extended-spectrum cephalosporins that are often 
used to treat patients with meningitis.1,8,12,39 Other antibiotics that S. pneumoniae have 
been found to be resistant to include erythromycin, tetracycline, chloramphenicol, and 
trimethoprim-sulfamethoxazole.1,4,6,39,47 There have been no reports of S. pneumoniae 
resistant to vancomycin, yet there is concern that vancomycin resistance could develop if 
this drug is overly prescribed for susceptible pneumococcal infections that could 
otherwise be treated with a more appropriate antibiotic (e.g., penicillin or a 
7cephalosporin).48-50 It is very important to obtain accurate susceptibility data on invasive 
pneumococcal infections so that appropriate drugs can be selected for treatment. 
 
Antimicrobial Susceptibility Testing of S. pneumoniae 
National Committee Of Clinical Laboratory Standards  
The National Committee of Clinical Laboratory Standards (NCCLS) is a 
nongovernment organization made up of volunteer members that represent the clinical 
laboratory testing community.51 The NCCLS periodically publishes documents called 
“standards” that describe laboratory procedures and interpretive criteria that are used as 
guidelines by clinical laboratories. These standards are based on published clinical data 
and represent a “consensus opinion of good laboratory practice.”51 Laboratories are 
encouraged to follow standards published by the NCCLS for susceptibility testing of S.
pneumoniae.11 The NCCLS cannot approve or endorse commercial products used by 
clinical laboratories. The Food and Drug Administration (FDA) is responsible for 
evaluating and approving commercial medical devices used by clinical laboratories, 
including those used for antimicrobial susceptibility testing.51,52 
Definitions of Antimicrobial Susceptibility 
The NCCLS has defined three interpretive categories that describe the susceptibility 
of an infecting organism to an antimicrobial drug: 1) susceptible, the bacterial infection 
should respond to therapy when treated with the antimicrobial drug at the recommended 
8dosage for that type of infection; 2) intermediate, the antimicrobial drug may be less 
effective for treating the infection, but may still be used for treating certain types of 
infections depending upon the site of infection; and 3) resistant (also referred to as highly 
resistant), the antimicrobial drug does not inhibit the infecting organism when normal 
dosage schedules are used.53-55 In addition, the CDC defines isolates that are intermediate 
or resistant to an antimicrobial agent as nonsusceptible to that agent.56 
Susceptibility Testing Methods 
Susceptibility testing methods used to detect penicillin resistance in S. pneumoniae 
include qualitative screening methods to initially identify nonsusceptible isolates and 
quantitative testing methods to precisely define the level of penicillin susceptibility. 
 Qualitative susceptibility screening methods. The most frequently used qualitative 
screening method for penicillin susceptibility is oxacillin disk diffusion. This method has 
been standardized by the NCCLS.53 Penicillin disk diffusion is not recommended 
because it cannot accurately detect penicillin-nonsusceptible isolates.57 Advantages of 
the oxacillin disk diffusion screening method include it being relatively inexpensive and 
simple to perform, and that it does not require any special equipment.58 S. pneumoniae 
isolates are placed on an agar plate with a paper disk containing 1 µg of oxacillin. Other 
disks containing additional antibiotics can be placed on the same plate.54 After 18 hours 
of incubation, the agar plates are inspected and zones of growth inhibition around each 
9antibiotic disk are measured to the nearest millimeter. An S. pneumoniae isolate with an 
oxacillin zone of  20 mm is considered susceptible to penicillin.51 
The major disadvantage with the oxacillin screening method is that it cannot 
quantify the level of penicillin resistance of S. pneumoniae, nor can it distinguish 
intermediate strains from strains that are resistant to penicillin.53,57 Isolates that have 
oxacillin zones of  19 mm must be tested by a quantitative susceptibility method to 
accurately quantify and confirm penicillin resistance.51 It is very important that isolates 
found nonsusceptible by oxacillin screening also be tested against an extended-spectrum 
cephalosporin (cefotaxime or ceftriaxone), since penicillin-nonsusceptible isolates are 
often nonsusceptible to other -lactam antibiotics, and cephalosporins are frequently used 
to treat invasive pneumococcal infections.11,12,51 
Another qualitative screening method is the breakpoint screening method.59 This is 
a variation of the NCCLS broth microdilution method (described below), and can be used 
by laboratories to initially identify isolates that are nonsusceptible to penicillin before 
broth microdilution is performed. The NCCLS has determined minimum inhibitory 
concentration (MIC) breakpoints that are used to categorize an isolate as susceptible, 
intermediate, or resistant to an antimicrobial drug. The MIC is the lowest concentration of 
an antibiotic that completely inhibits the visible growth of an organism in vitro.60 An 
isolate of S. pneumoniae with a penicillin MIC of  0.06 µg/ml is considered susceptible 
to penicillin.51 Thus, breakpoint screening is performed by placing S. pneumoniae in 
media containing 0.06 µg/ml of penicillin. If growth is inhibited at this concentration, 
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then the isolate is considered susceptible to penicillin, and if growth is not inhibited then 
it is considered penicillin-nonsusceptible. All isolates that are determined to be 
nonsusceptible by this method must have an exact MIC determined to classify the level of 
nonsusceptibility.61 
Quantitative susceptibility testing methods. Quantitative susceptibility testing 
involves the determination of an antimicrobial MIC. Traditionally this has been 
accomplished by broth microdilution, a method that has been standardized by the 
NCCLS.60 Isolates of S. pneumoniae are inoculated into the wells of a microdilution tray 
(macrodilution is performed in tubes) containing various serial dilutions (e.g., 8 µg/ml, 4 
µg/ml, 2 µg/ml) of one or more antimicrobial drugs. After an overnight incubation, an 
MIC is determined as the concentration of antibiotic for which there is no visible bacterial 
growth. Laboratories can prepare their own broth microdilution trays as described by the 
NCCLS,60 or they can use commercial broth microdilution systems that contain frozen or 
lyophilized dilutions of various antibiotics. Laboratories often use commercially-prepared 
broth microdilution trays because the preparation of broth microdilution trays as 
described by the NCCLS involves the use of lysed horse blood, which is tedious to 
prepare and not widely available from commercial sources.62 Although commercial 
microdilution systems are more convenient to use than the NCCLS broth microdilution 
method, many systems, especially automated ones, have been found to be unacceptable 
by researchers that have compared MIC test results obtained by commercial systems with 
results determined by the NCCLS method.62-65 
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The E test (AB Biodisk, Solna, Sweden), also called agar gradient diffusion, was 
approved for use by the FDA in 1991.66 It has become a popular alternative to the broth 
microdilution method and has been highly recommended in the literature as a method for 
determining MICs because of its convenience and reliability.63-65,67-72 However, the 
NCCLS cannot officially recommend it because it is a commercial product. The E test 
uses a plastic strip that contains a continuous gradient of antibiotic to be tested. The strip 
is placed on the surface of an agar plate inoculated with S. pneumoniae. Additional strips 
can be placed on the same plate. After an overnight incubation, an antibiotic gradient is 
produced resulting in an elliptic zone of growth inhibition. The MIC value is read where 
the ellipse of inhibition intercepts the test strip. 
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METHODS 
Surveillance of Penicillin-Resistant S. pneumoniae 
In August 1993, questionnaires were sent to all 44 hospitals with clinical 
microbiology laboratories in Connecticut. Laboratories that did not respond to the 
questionnaire were contacted by telephone. To determine the prevalence of penicillin 
resistance among isolates of S. pneumoniae, laboratories were asked to report the number 
of isolates tested by an MIC method for penicillin susceptibility from July 1992 through 
June 1993, the body site of these isolates, and the penicillin MIC value (µg/ml).  
 Active surveillance for invasive S. pneumoniae isolates identified by 35 acute-care 
hospital laboratories in Connecticut was established in March 1995. Hospital laboratories 
were required to submit all invasive (i.e., obtained from normally sterile sites) 
pneumococcal isolates to the State Laboratory and to report the results of penicillin 
susceptibility tests performed on these isolates to the CDPH. Isolates submitted from 
March 1995 through February 1996 were sent to a CDC-contracted reference laboratory 
for antimicrobial susceptibility testing by the broth microdilution method described by the 
NCCLS.60 
All isolates tested either by the reference laboratory or by a hospital laboratory 
were categorized into penicillin susceptibility categories based on MIC breakpoints 
defined by the NCCLS: susceptible (MIC  0.06 µg/ml), intermediate (MIC 0.1 to 1.0 
µg/ml), and resistant (MIC  2.0 µg/ml). Isolates with MICs of  0.1 µg/ml were classified 
as nonsusceptible.51,56 
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Evaluation of Hospital Laboratory Susceptibility Testing Practices 
 To determine practices used by Connecticut hospital laboratories for penicillin 
susceptibility testing of S. pneumoniae, the laboratory questionnaire sent to hospital 
laboratories in 1993 asked whether pneumococcal isolates received in their laboratory 
were tested for penicillin susceptibility, where isolates were tested, what criteria were 
used to select pneumococcal isolates for susceptibility testing, and what susceptibility 
methods were used to detect penicillin resistance. 
 In June 1995, a similar questionnaire was mailed to all 35 acute-care hospital 
clinical microbiology laboratories in Connecticut. Laboratories that did not respond were 
contacted by telephone. Additional questions included on the 1995 questionnaire asked 
what type of test was used for MIC determination and if additional antimicrobial MICs 
were determined on S. pneumoniae isolates identified as oxacillin or penicillin-
nonsusceptible. Comparison of susceptibility testing practices between 1993 and 1995 
were limited to the 35 acute-care hospital laboratories surveyed in both years. 
 To determine the accuracy of susceptibility test results reported by hospital 
laboratories in 1995-1996, categorical susceptibility test results reported by hospital 
laboratories were compared with those determined by the reference laboratory. Isolates 
tested by an MIC method were categorized as susceptible (S), intermediate (I), or resistant 
(R) as described above. Isolates tested by oxacillin disk diffusion were categorized using 
14
interpretive criteria defined by the NCCLS: susceptible (S, oxacillin zone  20 mm) and 
nonsusceptible (NS, oxacillin zone  19 mm).51 
Comparison of reference laboratory penicillin and hospital laboratory oxacillin 
categorical results were characterized as follows: concordant (penicillin S by reference 
laboratory and oxacillin S by hospital laboratory, or penicillin NS by reference laboratory 
and oxacillin NS by hospital laboratory), false nonsusceptible (penicillin S by reference 
laboratory and oxacillin NS by hospital laboratory), or false susceptible (penicillin NS by 
reference laboratory and oxacillin S by hospital laboratory).57 False nonsusceptible results 
were assessed among all isolates categorized as susceptible by the reference laboratory, and 
false susceptible results were assessed among all isolates categorized as nonsusceptible by 
the reference laboratory. 
 Comparison of penicillin MIC categorical results determined by the reference 
laboratory and by hospital laboratories were characterized as follows: concordant (same 
categorical result by reference laboratory and hospital laboratory), very major error (R by 
reference laboratory and S by hospital laboratory), major error (S by reference laboratory 
and R by hospital laboratory), or minor error (S or R by reference laboratory and I by 
hospital laboratory, or I by reference laboratory and S or R by hospital laboratory).72 
Discordant results were expressed as the percentage of interpretative errors occurring 
among those isolates at risk for error as follows: very major errors (false susceptibility) were 
assessed among all isolates classified as resistant by the reference laboratory, major errors 
15
(false nonsusceptibility) were assessed among all isolates classified as susceptible by the 
reference laboratory, and minor errors were assessed among all isolates tested.71,73,74 
Data was analyzed using EpiInfo, Version 6 (CDC, Atlanta, Ga). The 2 test was 
used to test the significance of proportions. 
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RESULTS 
Prevalence of Penicillin Resistance in S. pneumoniae 
In 1992-1993, 14 hospital laboratories in Connecticut reported penicillin MIC 
data on 846 pneumococcal isolates from different body sites (Table 2). Hospital 
laboratories that did not report MIC values either did not perform MIC determinations in 
their laboratory or did not maintain records of MIC data. Of the 846 isolates, 18 (2.1%) 
were nonsusceptible to penicillin, including 15 (1.8%) penicillin-intermediate isolates and 
3 (0.4%) penicillin-resistant isolates. Of the 846 isolates, 400 (47%) were from normally 
sterile sites. Of these 400 isolates, 5 (1.3%) were nonsusceptible to penicillin including 4 
(1.0%) penicillin-intermediate isolates and 1 (0.3%) penicillin-resistant isolate. There 
were significantly more middle ear isolates classified as penicillin-nonsusceptible than 
isolates from other sites (P < 0.001). There were no other significant differences in the 
percentage of isolates classified as penicillin-nonsusceptible from other body sites. 
 Active hospital-based surveillance in 1995-1996 identified 801 cases of invasive 
pneumococcal disease. Penicillin MICs were determined by the CDC reference laboratory 
on 733 isolates from 705 cases. Of the 733 isolates, 119 (16.2%) were classified as 
nonsusceptible to penicillin, including 52 (7.1%) penicillin-intermediate isolates and 67 
(9.1%) penicillin-resistant isolates. This represents a 13-fold increase in invasive 
pneumococcal isolates nonsusceptible to penicillin in a three year period, and a 37-fold 
increase in S. pneumoniae highly resistant to penicillin. 
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Ten acute-care hospital laboratories surveyed in both years reported penicillin 
MICs on invasive pneumococcal isolates identified in their laboratories. The number and 
percentage of isolates determined by these hospital laboratories as penicillin-
nonsusceptible in 1992-1993 and 1995-1996 are presented in Table 3. With the exception 
of one hospital laboratory that did not report any nonsusceptible isolates in either year, the 
proportion of isolates identified as penicillin-nonsusceptible increased among all hospital 
laboratories. Overall the prevalence of isolates determined as nonsusceptible to penicillin 
by these hospital laboratories increased tenfold, from 1.3% in 1992-1993 to 12.8% in 
1995-1996 (P < 0.001). 
 
Hospital Laboratory Susceptibility Testing Practices, 1993 and 1995 
Penicillin Susceptibility Testing 
In 1993 and 1995, all 35 (100%) acute-care hospital microbiology laboratories in 
Connecticut responded to the laboratory surveys. In both years, 34 (97%) laboratories 
reported that pneumococcal isolates were routinely tested for penicillin susceptibility either 
in-house or at a reference laboratory. In 1993, one (3%) laboratory reported that penicillin 
susceptibility testing was not performed on any pneumococcal isolates. In 1995, one (3%) 
laboratory reported that isolates were tested only when specifically requested by a physician. 
Only results from the 34 laboratories that reported having susceptibility tests routinely 
performed on pneumococcal isolates will be presented. 
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The majority of hospital laboratories in both years reported testing pneumococcal 
isolates in-house; 29 (85%) in 1993, and 32 (94%) in 1995. In both years, the 34 hospital 
laboratories reported that they routinely tested all pneumococcal isolates from invasive sites. 
However, the number of laboratories testing all pneumococcal isolates from any body site 
significantly increased from 6 (18%) in 1993 to 23 (68%) in 1995 (P < 0.001). 
 Significant changes in susceptibility testing practices were observed between 1993 
and 1995 (Table 4). In both years, the majority of hospital laboratories using a qualitative 
screening method reported using oxacillin disk diffusion (19/22 in 1993, 27/28 in 1995). 
The number of laboratories that reported having an initial oxacillin screening test performed 
on isolates followed by penicillin MIC testing of oxacillin-nonsusceptible isolates increased 
from 7 (21%) in 1993 to 20 (59%) in 1995 (P < 0.005). The total number of laboratories 
that had penicillin MICs determined on pneumococcal isolates increased from 22 (65%) in 
1993  to 31 (91%) in 1995 (P < 0.05). 
 For laboratories that had isolates tested for penicillin susceptibility by a quantitative 
MIC method in 1995, 19 (61%) of 31 laboratories reported having isolates tested with the E 
test and 12 (39%) had isolates tested with a broth microdilution method. No laboratories 
reported using an automated method for MIC testing. The type of MIC testing method used 
was not asked of hospital laboratories in the 1993 survey.
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Accuracy Of Oxacillin Disk Diffusion 
A total of 733 pneumococcal isolates were submitted by hospital laboratories and 
MIC tested at the CDC-contracted reference laboratory. Hospital laboratories reported 
oxacillin zone diameters on 440 (60%) of these isolates. Categorical oxacillin results were 
compared with reference laboratory categorical penicillin results (Table 5).  Overall, 415 
(94%) of the oxacillin categorical results were concordant with the reference laboratory 
penicillin susceptibility classifications. All isolates categorized as penicillin-resistant by the 
reference laboratory were correctly identified as nonsusceptible by hospital oxacillin 
screening. Discordant results by oxacillin screening were 5.7% (21/367) false 
nonsusceptible, and 5.5% (4/73) false susceptible. Of the 21 false nonsusceptible results, 14 
(67%) isolates were further penicillin MIC tested and correctly identified as penicillin-
susceptible by hospital laboratories, 3 (14%) were identified as penicillin-intermediate by 
hospital laboratories, and 4 (19%) were not MIC tested. None of the four isolates falsely 
classified as susceptible by oxacillin screening were further MIC tested by hospital 
laboratories. All four of these isolates had reference laboratory penicillin MICs that were at 
the breakpoint for intermediate resistance (MIC of 0.1 µg/ml). 
 
Accuracy of Penicillin MIC Testing 
Connecticut hospital laboratories reported penicillin MIC results on 432 (59%) of 
the 733 pneumococcal isolates tested by the reference laboratory. Of these 432 isolates, 310 
(72%) were tested by the E test and 122 (28%) by broth microdilution. The comparison of 
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hospital and reference laboratory categorical penicillin MIC results are presented in Table 6. 
Overall, 383 (89%) of the hospital laboratory MIC results were concordant with the 
reference laboratory results. There were no very major errors, 0.9% (3/325) major errors, 
and 10.6% (46/432) minor errors for all isolates tested by an MIC method by hospital 
laboratories. For isolates tested by hospital laboratories using broth microdilution there were 
3.9% (3/76) major errors and 11.5% (14/122) minor errors. The majority of these minor 
errors (10 of 14) were isolates defined as resistant by the reference laboratory but interpreted 
as intermediate by hospital laboratories. For isolates that were tested by the E test by 
hospital laboratories, there were no major errors and 10.3% (32/310) minor errors, including 
15 isolates categorized as intermediate by the reference laboratory but susceptible by 
hospital laboratories, and 12 isolates categorized as resistant by the reference laboratory but 
intermediate by hospital laboratories. 
 
Susceptibility Testing Against Other Antimicrobial Agents 
In 1995, 20 (59%) of the 34 acute-care hospital laboratories reported that they 
determined MIC values for antimicrobial agents clinically indicated for the treatment of S. 
pneumoniae in addition to penicillin.51 Fourteen (41%) laboratories indicated that 
additional antimicrobial MICs were determined on a routine basis for any isolates found to 
be nonsusceptible by oxacillin screening or penicillin MIC determination. MIC testing 
against an extended-spectrum cephalosporin (cefotaxime or ceftriaxone) was performed by 
14 (41%) laboratories, against chloramphenicol by 10 (29%) laboratories, erythromycin by 
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10 (29%), trimethoprim-sulfamethoxazole by 9 (26%), vancomycin by 8 (24%), tetracycline 
by 7 (21%), imipenem by 5 (15%), clindamycin by 1 (3%) and ofloxacin by 1 (3%) 
laboratory. No laboratories reported MIC testing against rifampin. 
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DISCUSSION 
The prevalence of penicillin-resistant S. pneumoniae increased substantially in 
Connecticut from 1992 to 1996. The comparison of prevalence data from the 1992-1993 
survey with the 1995-1996 survey is somewhat limited in that the first survey relied on MIC 
data determined by hospital laboratories, and less than half of the acute-care hospital 
laboratories in Connecticut could provide this data in 1993. However, comparison of 
penicillin susceptibility data from hospital laboratories that determined penicillin MICs in 
both years also showed that there was a substantial increase in invasive S. pneumoniae 
identified as nonsusceptible to penicillin. Several other studies have also demonstrated a 
marked increase during this time period in pneumococci resistant to penicillin and other 
antimicrobial agents.1,4-8 The proportion of isolates determined as nonsusceptible to 
penicillin in 1995-1996 in Connecticut was 16%. This is similar to that reported from New 
York City in 1995,38 and to two national surveillance studies from 1993-1994.1,33 The 
prevalence of isolates (highly) resistant to penicillin in Connecticut during this period was 
9%, which is similar to that reported from a national surveillance study from 1994-1995.6
The sharp increase in strains resistant to penicillin observed by this study may be 
due to selective pressure resulting from the widespread use of antibiotics.1,75 Pneumococci, 
like all bacteria, are constantly reproducing and chromosomal mutations involving the 
alteration of penicillin binding proteins allow pneumococci to become less susceptible or 
totally resistant to penicillin and other -lactam antibiotics.76,77 Once a resistant strain 
develops, genes that encode for antibiotic resistance can be easily transferred from resistant 
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S. pneumoniae to susceptible S. pneumoniae, as well as to and from other bacterial species.2
In the presence of antibiotics, susceptible pneumococci are killed while resistant strains are 
selected to survive and multiply. 
 Studies have demonstrated that prior use of antibiotics is associated with carriage 
and infection of penicillin-nonsusceptible S. pneumoniae.34,37,43-45,78 Young children, 
particularly those attending day care, often develop respiratory tract infections and otitis 
media and frequently receive antibiotics that may select for drug-resistant strains.2 A survey 
of antimicrobial prescription practices among office-based physicians in the United States 
found that from 1980 to 1992, annual visit rates for otitis media among children under 15 
years increased significantly.79 Otitis media was the most common diagnosis for which an 
antimicrobial drug was prescribed. This survey also found that the use of narrower-spectrum 
drugs such as penicillin decreased, and the use of broader-spectrum antibiotics such as 
cephalosporins increased.79 Inappropriate use of antibiotics such as prescribing antibiotics 
for viral infections and prescribing overly broad-spectrum antibiotics can lead to the 
development of resistant strains.80 A study by Yu et al determined that 35% of antibiotic 
prescriptions for the empirical treatment of patients hospitalized with bacteremia were 
unacceptable, with physicians often selecting the broadest possible antibiotic coverage to 
ensure elimination of the infecting organism.81 
Due to the increasing prevalence of drug-resistant strains of S. pneumoniae, clinical 
microbiology laboratories must be able to accurately determine the antimicrobial 
susceptibility of S. pneumoniae. As part of a national strategy to minimize the impact of 
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drug-resistant S. pneumoniae, the CDC has emphasized the need for clinical laboratories to 
adhere to interpretive standards published by the NCCLS and to use appropriate methods 
for the susceptibility testing of S. pneumoniae.11,80 Since there are a variety of methods 
laboratories can use to test isolates for penicillin susceptibility, it is important to know 
which methods laboratories are using and the accuracy of hospital laboratory susceptibility 
test results. There have been many studies published that have assessed the ability of 
various susceptibility methods to determine the penicillin susceptibility of S. pneumoniae;
the susceptibility tests were, however, often performed by researchers in a single laboratory 
using a selected set of pneumococcal isolates.57,62-65,68-70,82-86 We were able to determine the 
accuracy of susceptibility testing performed by hospital laboratories by comparing 
susceptibility data determined by a CDC-contracted reference laboratory with test results 
determined by hospital laboratories using data on isolates collected as part of an active 
surveillance program. 
 Results of the laboratory surveys show that 97% of Connecticut hospital laboratories 
in both 1993 and 1995 reported routinely having pneumococcal isolates tested for penicillin 
susceptibility. Our results indicate that there was a significant increase between 1993 and 
1995 in the number of hospital laboratories that reported using a combination of oxacillin 
screening followed by penicillin MIC determination of oxacillin-nonsusceptible isolates. 
This practice is recommended by the NCCLS.51 
Oxacillin screening by hospital laboratories accurately identified all penicillin-
resistant isolates, but four penicillin-intermediate isolates were misclassified as oxacillin-
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susceptible, resulting in 5.5% false susceptibility. However, all four of these isolates had 
reference penicillin MIC values at the intermediate breakpoint (0.1 µg/ml). The occurrence 
of these discordant results at the penicillin-intermediate breakpoint lessens their clinical 
significance. Previous studies conducted in research settings have found few oxacillin false 
susceptible results.57,63,82,87-89 Hospital laboratories had 5.7% oxacillin false nonsusceptible 
results, less than the 11% to 14% observed in other studies.87-89 The majority of false 
nonsusceptible isolates were correctly identified as susceptible upon penicillin MIC testing, 
with only three isolates (14%) still being classified as penicillin-nonsusceptible 
(intermediate) by the hospital laboratories. Again, these misclassifications probably have 
limited clinical significance. 
 The E test was used by more hospital laboratories than broth microdilution for 
penicillin MIC determination in 1995. This is probably because broth microdilution, as 
mentioned previously, can be difficult and tedious for laboratories to perform on a routine 
basis.2,62 While the use of the E test cannot be officially recommended by the NCCLS 
(because it is a commercial product), it has been found to be a reliable alternative to broth 
microdilution for determining penicillin MICs.63-65,68,71,72 Our study found good agreement 
between penicillin E test MIC results determined by hospital laboratories and penicillin 
broth microdilution MIC results determined by the reference laboratory. There were 10.3% 
minor errors, with no major or very major errors, a result consistent with previous studies 
that have evaluated the accuracy of the E test.63,71,72 Intermediate isolates that were 
misclassified by hospital laboratories as susceptible are of concern because this type of 
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discordant result could effect the treatment of pneumococcal meningitis. The recommended 
therapy for pneumococcal meningitis caused by a penicillin-intermediate strain differs from 
that for a penicillin-susceptible strain.12 
Hospital laboratories determining MICs by broth microdilution produced slightly 
more interpretive errors than observed with the E test. There were no very major errors, 
3.9% major errors, and 11.5% minor errors noted. Susceptible isolates that were falsely 
classified as resistant (major errors) are of concern because some patients may have been 
treated with a broader-spectrum antibiotic than needed. Inappropriate antibiotic use, 
including the use of overly broad-spectrum antimicrobial drugs can contribute to the 
increase of drug-resistant S. pneumoniae.1,11 The 1995 laboratory survey did not address the 
specific methodologies used by hospital laboratories for broth microdilution testing, such as 
what media was used and whether the microdilution plates were prepared in-house or 
obtained commercially. Differences in testing methodologies and the use of various 
commercial testing systems could account for the discrepancies observed between the 
hospital laboratory broth microdilution results and those of the reference laboratory.62-65,85 
Only 41% of hospital laboratories in Connecticut reported that they would have a 
pneumococcal isolate that was oxacillin- or penicillin-nonsusceptible MIC tested against an 
extended-spectrum cephalosporin (cefotaxime or ceftriaxone).  This finding is disappointing 
since current NCCLS and CDC recommendations are that isolates determined as penicillin-
nonsusceptible should be quantitatively susceptibility tested against an extended-spectrum 
cephalosporin.11,51,56 This is especially important for patients with pneumococcal 
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meningitis because treatment failures in meningitis caused by cephalosporin-nonsusceptible 
S. pneumoniae have been reported.10,90-92 For such patients, the American Academy of 
Pediatrics currently recommends additional susceptibility testing against vancomycin, 
meropenem, and rifampin.12 For nonmeningeal invasive infections caused by penicillin-
resistant S. pneumoniae, susceptibility testing for vancomycin, rifampin, erythromycin, 
trimethoprim-sulfamethoxazole, clindamycin, imipenem, meropenem, and chloramphenicol 
should be considered.12 
With the increasing prevalence of penicillin-resistant S. pneumoniae in Connecticut, 
it is very important that clinical microbiology laboratories be able to accurately detect 
penicillin resistance. The study presented here shows that most acute-care hospital 
laboratories in Connecticut were using appropriate and accurate methods to test 
pneumococcal isolates for penicillin susceptibility. As recommended by the NCCLS, 
laboratories that use a qualitative screening method need to confirm nonsusceptibility 
with a quantitative MIC method, a laboratory practice that was performed by significantly 
more laboratories in 1995 than in 1993. Susceptibility test results determined by hospital 
laboratories by oxacillin screening, the E test, and broth microdilution produced relatively 
few discrepancies. Of concern are susceptibility misclassifications that could result in 
inappropriate antimicrobial therapy. The changes in laboratory practice observed between 
1993 and 1995 indicate that laboratories are adapting to recommendations for 
susceptibility testing of S. pneumoniae, which is critical in this era of increasing 
antimicrobial resistance. Pneumococcal isolates, especially invasive isolates found to be 
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penicillin-nonsusceptible, need to be routinely MIC tested against an extended-spectrum 
cephalosporin. Additional antimicrobial MICs may need to be determined depending on the 
site of infection and the prevalence of resistance in the local community. This study did not 
test the proficiency of hospital laboratories to identify pneumococcal strains with known 
levels of penicillin susceptibility or resistance, and so cannot comment further on specific 
laboratory practices that may have lead to susceptibility misclassifications. 
 Penicillin-resistant S. pneumoniae will most likely continue to increase in 
Connecticut and in other parts of the United States. In 1994, the CDC formed a working 
group to develop a strategy to minimize the impact of drug-resistant S. pneumoniae.11 
Surveillance for drug-resistant S. pneumoniae, such as done in Connecticut, was listed as 
the first goal of the plan. Continued surveillance is warranted to detect changing patterns 
of pneumococcal resistance and to identify populations most as risk for infection with 
resistant strains of S. pneumoniae. Information gained from the surveillance of 
antimicrobial resistance can be used to increase the awareness of the problem among 
health care providers and to promote the judicious use of antibiotics. 
 Part of the CDC’s goal to improve and expand the surveillance of drug-resistant S.
pneumoniae in the United States is to make certain that clinical laboratories are using 
appropriate and accurate methods for susceptibility testing of pneumococcal isolates.11 
The study presented in this paper addressed this issue and determined that most 
laboratories in Connecticut are using appropriate methods for penicillin susceptibility 
testing of S. pneumoniae, and should also be encouraged to expand susceptibility testing 
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with additional antimicrobial agents. These findings will hopefully be published in a 
clinical laboratory-oriented journal. 
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TABLE 1Surveys of Resistance to Penicillin Among Isolates of S. Pneumoniae,
United States, 1979-1995 
Isolates 
 
No. 
Penicillin 
nonsusceptiblea
Location  Year(s) surveyed isolates I, % R, % Total % Ref.
19 hospitals in 26 statesb 1979-1987 any site 5469 5.0 0.02 5.0 9
Dallasc 1981-1983 sterile site 258 8.1 0 8.1 34
Oklahoma 1989-1990 sterile site 144 6.3 1.4 7.6 35
13 hospitals in 12 statesb 1991-1992 sterile site 544 5.4 1.3 6.6 4
17 medical centers in U.S.  1991-1992 any site 524 15.2 2.6 17.8 7
19 laboratories in 17 states 1992-1993 resp. tract 799 14.9    7.3 22.2 32
Washington, DCc 1992-1993 sterile site 108 8.3 4.6 12.9 36
St. Louisc 1992-1993 any site 136 19.9 5.9 25.7 37
New York Cityd 1993 any site 1229 5.7 1.5 7.2 38
12 hospitals in 11 statesb 1993-1994 sterile site 740 10.8 3.2 14.1 1
33 laboratories in 19 states 1993-1994 any site 1627 10.4 5.7 16.2 33
Atlanta 1994 sterile site 431 17.9 7.4 25.3 39
30 institutions in 23 states 1994-1995 any site 1527 14.1 9.5 23.6 6
New York Cityd 1995 any site 3535 8.8 6.3 15.0 38
24 institutions in 16 states 1995 any site 592 6.1 21.1 27.2 8
a I, intermediate; R, resistant (also called highly resistant). 
 b Data from CDC sentinel surveillance. 
 c Isolates from pediatric patients only. 
 d Susceptibility testing performed by hospital laboratories and results reported to health 
department. 
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TABLE 2Prevalence of Penicillin Resistance Among Isolates of S. pneumoniae 
 from Different Body Sites, 1992-1993 
 Nonsusceptiblea
Site No. isolates I (%) R (%) Total (%)
Blood or cerebrospinal fluid 385b 4 (1.0) 1 (0.3) 5 (1.3) 
Pleural, peritoneal, pericardial, 
or joint 
 
15b 0 0 0
Middle Ear 10 3 (30) 0 3 (30) 
Eye 25 0 0 0 
Transtracheal, nasopharyngeal, 
or sputum 
 
319 
 
7 (2.2) 
 
2 (0.6) 
 
9 (2.8) 
Other or unspecified 92 1 (1.1) 0 1 (1.1) 
 Total 846 15 (1.8) 3 (0.4) 18 (2.1) 
a I, penicillin-intermediate; R, penicillin-resistant (highly resistant). 
 b from normally sterile body sites. 
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TABLE 3Prevalence of Penicillin Resistance Among S. pneumoniae 
Isolates from Normally Sterile Sites MIC Tested by 10 Hospital 
 Laboratories, 1992-1993 and 1995-1996 
 1992-1993  1995-1996 
Hospital No. isolates NSa (%)   No. isolates NSa (%)  
A 3 0 11 2 (18.2) 
B 52 3 (5.8)  50 9 (18.0) 
C 20 0 26 2 (7.7) 
D 23 0 21 4 (19.0)*** 
E 57 1 (1.8)  33 8 (24.2)** 
F 38 0 40 0
G 18 1 (5.6)  12 3 (25.0) 
H 28 0 33 4 (12.1) 
I 21 0 9 5 (55.6)*
J 134 0 93 5 (5.4)*** 
Total 394 5 (1.3)  328 42 (12.8)*
a NS, penicillin-nonsusceptible, includes penicillin-intermediate and  
 penicillin-resistant isolates. 
 *P < .001; **P < .005; ***P < .05
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TABLE 4Methods Used by 34 Connecticut Hospital Laboratories for 
 Penicillin Susceptibility Testing of S. pneumoniae, 1993 and 1995 
 No. (%) laboratories 
Method(s) 1993 1995 
Oxacillin disk screening only 11 (32) 3 (9)*
Penicillin disk screening only 1 (3) 0 
Oxacillin disk screening and MIC testing of NSa isolates 7 (21) 20 (59)** 
Breakpoint screeningb and MIC testing of NSa isolates 2 (6) 1 (3) 
Oxacillin disk screening; MIC testing by request only 1 (3) 4 (12) 
MIC testing without an initial screening test 12 (35) 6 (18) 
 a NS, isolates identified as nonsusceptible by a screening test.  
 b 0.06 Lg/ml penicillin in Mueller-Hinton broth with 5% lysed horse blood. 
 * P <.05; ** P < .005.
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TABLE 5Comparison of Oxacillin Screening by Connecticut Hospital 
 Laboratories and Penicillin MIC Testing by the Reference Laboratory 
 for 440 S. pneumoniae Isolates 
 Susceptibility classifications of isolates tested by 
oxacillin screening by hospital laboratories (oxacillin 
diameter)  
Reference laboratory 
determinations a (No.) 
Susceptible 
( 20 mm) 
Nonsusceptible 
( 19 mm) 
Susceptible (367) 346 21 
Intermediate (31)b 4 27 
Resistant (42)b 0 42 
a by the NCCLS broth microdilution method (60). 
 b penicillin-nonsusceptible. 
 Boldface type indicates concordant results. 
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TABLE 6Comparison of Penicillin MIC Testing of S. pneumoniae Isolates by 
 Connecticut Hospital Laboratories and by the Reference Laboratory 
MIC method used by 
hospital laboratories 
 
Reference laboratory 
Penicillin susceptibility classifications of  
isolates MIC tested by hospital laboratories 
(No. isolates tested) determinationsa (No.) Susceptible Intermediate Resistant 
Broth microdilution Susceptible (76) 71 2 3
(n = 122) Intermediate (16) 1 14 1
Resistant (30) 0 10 20 
 
E test Susceptible (249) 245 4 0
(n = 310) Intermediate (27) 15 11 1
Resistant (34) 0 12 22 
 
Total  Susceptible (325) 316 6 3
(n = 432) Intermediate (43) 16 25 2
Resistant (64) 0 22 42 
 a by the NCCLS broth microdilution method (60). 
 Boldface type indicates concordant results. 
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